Note 2 - Significant Accounting Policies (Details Textual) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2024 |
Dec. 31, 2025 |
Jan. 31, 2025 |
Oct. 23, 2024 |
|||
| Insurance Premiums Dues Subscription and Software Cost Paid In Advance | $ 10,000 | $ 10,000 | ||||||||
| Cash, FDIC Insured Amount | $ 250,000 | $ 250,000 | ||||||||
| Weighted Average Number of Shares Outstanding, Basic (in shares) | [1] | 8,542,450 | 6,998,082 | 8,538,966 | 6,992,761 | |||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 823,127 | 754,939 | ||||||||
| Research and Development Expense | $ 4,766,832 | $ 1,730,000 | $ 8,254,079 | $ 3,373,375 | ||||||
| Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | 0 | $ 0 | ||||||||
| License Agreement [Member] | ||||||||||
| Initial Cash Payment for License Agreement | $ 1,000,000 | $ 1,000,000 | ||||||||
| Additional Cash Payment for License Agreement | $ 3,000,000 | $ 3,000,000 | ||||||||
| License Agreement, Upfront Payments [Member] | ||||||||||
| Research and Development Expense | 4,000,000 | |||||||||
| License Agreement, Value of Common Stock [Member] | ||||||||||
| Research and Development Expense | $ 4,600,000 | |||||||||
| Fair Value, Recurring [Member] | ||||||||||
| Liabilities, Fair Value Disclosure | $ 0 | $ 0 | $ 0 | |||||||
| ||||||||||
| X | ||||||||||
- Definition Represents the additional cash paid for the license agreement. No definition available.
|
| X | ||||||||||
- Definition The amount of cash initially paid for the license agreement. No definition available.
|
| X | ||||||||||
- Definition Represents insurance premiums dues subscription and software cost paid in advance. No definition available.
|
| X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. No definition available.
|
| X | ||||||||||
- Definition Fair value of financial and nonfinancial obligations. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|